Development of Structurally Identical Therapeutic and Diagnostic Agents for Image-Guided Boron Neutron Capture Therapy: c(RGD-BPA-K) Peptide with 125 I/ nat I Albumin-Binding Moiety
Molecular Pharmaceutics · 02.06.2025 · 22 (6) · 3423-3432
DOI: 10.1021/acs.molpharmaceut.5c00291 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 30.04.2025. Verfasst von Iqra Bibi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Applied RI, Korea Institute of Radiological & Medical Sciences (KIRAMS), 75 Nowon-ro, Nowon-gu, Seoul 01812, Republic of Korea. Hauptthemen laut MEDLINE: Boron Neutron Capture Therapy, Iodine Radioisotopes, Oligopeptides, Albumins. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: Korea Institute of Radiological and Medical Sciences.
Abstract (Originalsprache)
The development of boron neutron capture therapy (BNCT) agents and structurally similar radiolabeled counterparts for diagnostic imaging is an area of significant interest. In this study, we designed structurally same compounds, c(RGD-BPA-K)(PEG2-(4-iodophenylbutyl)) (compound 1) and its radioiodinated counterpart, c(RGD-BPA-K)(PEG2-(4-[125I]iodophenylbutyl)) ([125I]1), for efficient BNCT and SPECT/CT imaging, respectively. An albumin-binding moiety was introduced into the compound to enhance the blood circulation time and tumor accumulation. We evaluated the efficacy of compound 1 and [125I]1 in U87MG tumor-bearing mice using SPECT/CT imaging, biodistribution analysis, and inductively coupled plasma mass spectrometry. Both compound 1 and [125I]1 displayed similar pharmacokinetics, high blood retention, and substantial accumulation in U87MG tumors. This study highlights the potential of compound 1 and [125I]1 for SPECT/CT-guided BNCT. The structural identity between the therapeutic and diagnostic agents in BNCT can enhance its therapeutic efficacy. Further structural modifications to increase boron concentration in tumors, as well as thermal neutron irradiation studies, may be necessary to fully explore the potential of our novel BNCT agent.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Applied RI, Korea Institute of Radiological & Medical Sciences (KIRAMS), 75 Nowon-ro, Nowon-gu, Seoul 01812, Republic of Korea.
- University of Science and Technology (UST), 217, Gajeong-ro, Yuseong-gu, Daejeon 34113, Republic of Korea.
- Department of Chemistry, Pakistan Institute of Engineering and Applied Sciences (PIEAS), P. O. Nilore, Islamabad 45650, Pakistan.
ORCID-Profile: Jung Young Kim, Sajid Mushtaq, Ji-Ae Park
Förderung
- Korea Institute of Radiological and Medical Sciences
Zitieren
APA
Bibi, I., Kang, K. J., Kim, J. Y., Mushtaq, S., & Park, J. A. (2025). Development of Structurally Identical Therapeutic and Diagnostic Agents for Image-Guided Boron Neutron Capture Therapy: c(RGD-BPA-K) Peptide with 125 I/ nat I Albumin-Binding Moiety. Molecular Pharmaceutics, 22(6), 3423-3432. https://doi.org/10.1021/acs.molpharmaceut.5c00291
Vancouver
Bibi I, Kang KJ, Kim JY, Mushtaq S, Park JA. Development of Structurally Identical Therapeutic and Diagnostic Agents for Image-Guided Boron Neutron Capture Therapy: c(RGD-BPA-K) Peptide with 125 I/ nat I Albumin-Binding Moiety. Molecular Pharmaceutics. 2025;22(6):3423-3432. doi:10.1021/acs.molpharmaceut.5c00291
BibTeX
@article{Bibi2025,
author = {Bibi, Iqra and Kang, Kyung Jun and Kim, Jung Young and Mushtaq, Sajid and Park, Ji-Ae},
title = {Development of Structurally Identical Therapeutic and Diagnostic Agents for Image-Guided Boron Neutron Capture Therapy: c(RGD-BPA-K) Peptide with 125 I/ nat I Albumin-Binding Moiety},
journal = {Molecular Pharmaceutics},
year = {2025},
volume = {22},
number = {6},
pages = {3423--3432},
doi = {10.1021/acs.molpharmaceut.5c00291}
}
EUVIMED